{"groups":[{"description":"Participants received CAEL-101 500 milligrams (mg)/square meter (m\\^2) administered weekly as an intravenous (IV) infusion the first 4 weeks (dose limiting toxicity \\[DLT\\] observation period), and thereafter received CAEL-101 at the recommended phase 3 dose (RP3D) (1000 mg/m\\^2) every other week until the end of study, in combination with the standard of care (SoC) CyBorD (cyclophosphamide, bortezomib, dexamethasone) chemotherapy.","id":"FG000","title":"Part A: CAEL101 500 mg/m^2 Combined With SoC CyBorD"},{"description":"Participants received CAEL-101 750 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks (DLT observation period), and thereafter received CAEL-101 at the RP3D (1000 mg/m\\^2) every other week until the end of study, in combination with the SoC CyBorD chemotherapy.","id":"FG001","title":"Part A: CAEL101 750 mg/m^2 Combined With SoC CyBorD"},{"description":"Participants received CAEL-101 1000 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks (DLT observation period), and then every other week until the end of study, in combination with the SoC CyBorD chemotherapy.","id":"FG002","title":"Part A: CAEL101 1000 mg/m^2 Combined With SoC CyBorD"},{"description":"Participants received CAEL-101 at the RP3D (1000 mg/m\\^2) administered weekly as an IV infusion for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab.","id":"FG003","title":"Part B: CAEL-101 Combined With SoC CyBorD and Daratumumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"0"}],"type":"Received At Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"0"}],"comment":"Study Completion","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"DLT Observation Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Other than specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Continued Treatment Period"}]}